Wang W - Search Results

1

Combination of fruquintinib with venetoclax for the treatment of colorectal cancer.

Zhang W, Wang W, Wang R, Han X, Zhu L, Guo W, Gu Y. Zhang W, et al. Among authors: wang w, wang r. Oncol Res. 2024 Dec 20;33(1):225-234. doi: 10.32604/or.2024.050047. eCollection 2025. Oncol Res. 2024. PMID: 39735667 Free PMC article.

2

Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.

Han X, Wang W, Wang R, Zhang W, Zhu L, Xu Q, Guo W, Gu Y. Han X, et al. Among authors: wang w, wang r. Biochem Biophys Res Commun. 2024 May 21;709:149812. doi: 10.1016/j.bbrc.2024.149812. Epub 2024 Mar 26. Biochem Biophys Res Commun. 2024. PMID: 38564942

3

Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.

Cai P, Guo W, Yuan H, Li Q, Wang W, Sun Y, Li X, Gu Y. Cai P, et al. Among authors: wang w. Biomed Pharmacother. 2014 Apr;68(3):285-90. doi: 10.1016/j.biopha.2013.10.012. Epub 2013 Nov 12. Biomed Pharmacother. 2014. PMID: 24439672

4

Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression.

Wang W, Guo W, Li L, Fu Z, Liu W, Gao J, Shu Y, Xu Q, Sun Y, Gu Y. Wang W, et al. Biochem Pharmacol. 2016 Dec 1;121:8-17. doi: 10.1016/j.bcp.2016.09.024. Epub 2016 Oct 1. Biochem Pharmacol. 2016. PMID: 27693317

5

A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.

Wu X, Xu L, Li X, Zhou Y, Han X, Zhang W, Wang W, Guo W, Liu W, Xu Q, Gu Y. Wu X, et al. Among authors: wang w. Cell Death Dis. 2023 Aug 24;14(8):550. doi: 10.1038/s41419-023-06073-8. Cell Death Dis. 2023. PMID: 37620320 Free PMC article.

6

Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.

Wang W, Wang R, Han X, Zhang W, Zhu L, Gu Y. Wang W, et al. Among authors: wang r. Medicine (Baltimore). 2024 Apr 5;103(14):e37693. doi: 10.1097/MD.0000000000037693. Medicine (Baltimore). 2024. PMID: 38579072 Free PMC article.

7

Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.

Yuan H, Cai P, Li Q, Wang W, Sun Y, Xu Q, Gu Y. Yuan H, et al. Among authors: wang w. Biomed Pharmacother. 2014 Jul;68(6):751-6. doi: 10.1016/j.biopha.2014.07.002. Epub 2014 Jul 12. Biomed Pharmacother. 2014. PMID: 25081318

8

Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway.

Yuan H, Meng X, Guo W, Cai P, Li W, Li Q, Wang W, Sun Y, Xu Q, Gu Y. Yuan H, et al. Among authors: wang w. Neoplasia. 2015 May;17(5):410-20. doi: 10.1016/j.neo.2015.04.002. Neoplasia. 2015. PMID: 26025664 Free PMC article.

9

CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings.

Li Q, Zhang X, Wang W, Li L, Xu Q, Wu X, Gu Y. Li Q, et al. Among authors: wang w. Toxicol Appl Pharmacol. 2015 Dec 1;289(2):133-41. doi: 10.1016/j.taap.2015.09.025. Epub 2015 Sep 30. Toxicol Appl Pharmacol. 2015. PMID: 26431797

10

Corrigendum to "Transmembrane bound-IL-15-promoted epithelial-mesenchymal transition in renal cancer cells requires the Src-dependent Akt/GSK3β/β-catenin pathway" [Neoplasia, 17(2015): 410-420].

Yuan H, Meng X, Guo W, Cai P, Li W, Li Q, Wang W, Sun Y, Xu Q, Gu Y. Yuan H, et al. Among authors: wang w. Neoplasia. 2021 May;23(5):457-460. doi: 10.1016/j.neo.2021.03.004. Epub 2021 Apr 17. Neoplasia. 2021. PMID: 33878704 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89,457 results

Search Page

Filters